Physician profile
Daniel Pace
NPI 1972567758
$1,595.19
in general payments reported to CMS, 2019-2025
18 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $243 · 2021: $138 · 2022: $83.74 · 2023: $546 · 2024: $195 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.22 |
| Education | $149.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $331.00 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $288.76 | 2023-2024 | |
| Amgen INC. | $152.45 | 2019-2025 | Repatha, Otezla |
| Pfizer INC. | $143.45 | 2019-2024 | |
| Novo Nordisk INC | $127.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $121.09 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $65.03 | 2019 | |
| Dexcom, INC. | $52.88 | 2021-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $45.25 | 2023-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $42.52 | 2020-2025 | Jardiance |
| Allergan, INC. | $36.63 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.45 | 2020-2024 | |
| Eisai INC. | $27.89 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.39 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.14 | 2023 | Intellis Adaptivestim |
| Ironwood Pharmaceuticals, INC | $18.66 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.